Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (not Galectin Therapeutics Inc.) for the reporting period ending December 30, 2008. The filing addresses significant corporate governance changes and regulatory status updates regarding the company's stock listing.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate events rather than financial performance data.
Material Changes
- Executive Departure: Theodore H. Zucconi, Ph.D., was terminated as President effective December 31, 2008. He remains a member of the Board of Directors.
- Delisting Action: The NYSE Alternext US denied the Company's appeal regarding non-compliance with Section 1003(a)(ii) of the Exchange's Company Guide. The Exchange will begin the de-listing process.
- Market Transfer: The Company anticipates its shares will be quoted on the Over-the-Counter Bulletin Board (OTCBB) and has initiated the listing process for that market.
Outlook, Risks, and Management Commentary
Management has confirmed the transition of the stock to the OTCBB or another market following the denial of the listing appeal. The Company will notify investors of the new stock symbol once available. The primary risk highlighted is the loss of exchange listing status due to non-compliance with continued listing rules.
Investor Verification Checklist
- Verify the new stock symbol and trading status on the OTCBB.
- Confirm the appointment of a new President to replace Dr. Zucconi.
- Review the specific details of the non-compliance with NYSE Alternext US Section 1003(a)(ii).
- Check subsequent filings for the Company's liquidity position, as this 8-K does not disclose financial metrics.